Clinical Efficacy of Thalidomide Combined with Prednisone in the Treatment of Ulcerative Colitis and its Impact on Intestinal Barrier Function and Inflammatory Indicators in Patients
[Objective]To investigate the clinical efficacy of thalidomide combined with prednisone in the treatment of ulcerative colitis(UC)and its effects on intestinal barrier function and inflammatory indicators in patients.[Methods]A ret-rospective analysis was conducted on the clinical data of 92 UC patients admitted to our hospital 1 from April 2021 to March 2023.According to the treatment plan,they were divided into the control group(treated with prednisone in addition to con-ventional treatment)and the observation group(treated with thalidomide in addition to the control group),with 46 patients in each group.After 8 weeks of treatment,the efficacy,disease-related scores(Mayo endoscopic score,UC endoscopic se-verity index(UCEIS)score),intestinal barrier function related indicators[diamine oxidase(DAO),blood lactate(LAC),bacterial lipopolysaccharide(LPS),D-lactate(D-LA)],inflammation related indicators[Toll like receptor 4(TLR-4),nuclear factor kappa B(NF-κB),soluble late glycation end product receptor(sRAGE)],and adverse reactions were com-pared between the two groups.[Results]The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P＜0.05).After treatment,the Mayo score and UCEIS score of both groups were lower than before treatment,and the observation group was lower than the control group,with statistical significance(P＜0.05);The levels of serum DAO,LAC,LPS,and D-LA in both groups were lower than before treat-ment,and the observation group was lower than the control group,with statistical significance(P＜0.05);The levels of NF-κB,TLR-4,and sRAGE in both groups were lower than before treatment,and the observation group was lower than the control group,with statistically significant differences(P＜0.05).There was no statistically significant difference in the total effective rate of adverse reactions between the two groups(P＞0.05).[Conclusion]The combination of thalido-mide and prednisone has a good therapeutic effect on UC,which can reduce intestinal mucosal inflammation,improve intes-tinal barrier function,and is relatively safe.
万方数据
维普
